The invention relates to the human therapeutic application of famotidine or its therapeutically acceptable salts for the treatment of depression or symptoms suggesting depression, including somatic depression, unipolar depression, functional diseases of psychic origin, atypical depression, dysthymia, bipolar affective disorders, seasonal depression and persistent mood disorder. The invention also relates to such application of a pharmaceutical composition and its manufacturing.

The invention relates to the human therapeutic application of famotidine or its therapeutically acceptable salts for the treatment of depression or symptoms suggesting depression, including somatic depression, unipolar depression, functional diseases of psychic origin, atypical depression, dysthymia, bipolar affective disorders, seasonal depression and persistent mood disorder. The invention also relates to such application of a pharmaceutical composition and its manufacturing.

There are provided novel, therapeutically active 4-(4-hydroxy-3-nitrophenyl)-4-oxo-(2E)-butenoic acid and 4-(4-hydroxy-3-nitrophenyl)-4-oxo-(2Z)-butenoic acid of formula (I), as well as their salts formed with H2 receptor antagonists, preferably their Famotidine salt, and pharmaceutical compositions containing these compounds. Furthermore, processes are described for the preparation of the above compounds and compositions, respectively. The compounds of formula (I) and salts thereof possess sign...

The invention relates to a novel gastric acid secretion-inhibiting and gastrocytoprotective pharmaceutical composition, which comprises as active ingredient a 10:1 to 1:10 mixture by weight of a compound of formula (II), wherein A means a group of formula (A1), wherein R stands for a hydrogen atom or a hydroxy, C1-4alkyl or alkoxy group

The invention relates to two morphologically homogeneous forms of Famotidine [chemical name: N-sulfamoyl-3-(2-guanidino-thiazole-4-yl-methylthio)-propionamidine]. Said forms are prepared by selective crystallization or precipitation.

The invention relates to a new process for the preparation of N-sulfamyl-3-(2-guanidinothiazol-4-yl-methylthio)-propionitrile (famotidine) of the formula (I) (I) by S-alkylation of 2-guanidino-thiazol-4-yl-methanethiol obtained from S-(2-guanidino-thiazol-4-yl-methyl)-isothiourea dihydrochloride of the formula (III) (III) by in situ treatment with a base, which comprises carrying out S-alkylation with a N-sulfamyl-3-halopropionamidine of the formula (II) (II) wherein X st...

The invention relates to new propionamidine derivatives of formula (I) (I) wherein X is halogen, and to a process for their preparation. According to the invention compounds of the formula (I) are prepared by reacting a 3-halopropionitrile of the formula (III) (III) wherein X is as defined above, with sulfamide of the formula (II) (II) in the presence of a hydrogen halide. Compounds of the formula (I) are useful intermediates in the preparation of famotidine.

The invention relates to two morphologically homogeneous forms of famotidine [N-sulfamoyl-3-(2-guanidino-thiazole-4-yl-methylthio)-propionamidine]. Said forms are prepared by selective crystallisation or precipitation.